Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Acurx Pharmaceuticals excels in Q1, eyes partnerships and funding

Acurx Pharmaceuticals showcased strong performance in Q1 2024 with positive data, successful FDA outcomes, and robust Phase III trial preparations.
While facing challenges in costs, timelines, and partnership negotiations, the company remains optimistic about its future prospects and strategic opportunities.
Strategic partnerships, regulatory advancements, and potential funding from the PASTEUR Act present avenues for growth and development in Acurx's antibiotic pipeline.
Overall, Acurx Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges effectively, and leverage opportunities for continued success.

Acurx Pharmaceuticals progresses ibezapolstat towards Phase III trials

Acurx Pharmaceuticals is advancing ibezapolstat towards Phase III trials for C. difficile infection treatment
Despite financial challenges, the company is actively seeking partnerships and funding opportunities
The successful Phase II meeting with the FDA and new patent grant are key milestones for Acurx
Optimism surrounds the potential impact of ibezapolstat on improving C. difficile treatment

Acurx Pharmaceuticals reports Q3 loss, eyes growth through innovation and partnerships

Acurx Pharmaceuticals faces challenges in addressing potential dilution concerns and providing detailed insights into regulatory initiatives and Phase III trials. However, the company's strong pipeline, successful FDA meeting, and focus on innovation position it well for growth and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 28 to January 30, 2025 at the Borgata Hotel, Atlantic City, New Jersey.

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Following the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now also received written positive feedback from FDA regarding acceptability of our CMC (Chemistry Manufacturing and Controls) plan and data package proposed to support the Phase 3 clinical program Acurx has initiated the Scientific Advice procedure with the European Medicines Agency (EMA) to discuss the readiness for initiation of the Phase 3 clinical program in the European Union (EU). Acurx has been notified that we should expect to receive the final written advice letter in the coming few weeks Acurx is also in the process of discussing the pediatric development plans for ibezapolstat in C.

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Acurx Pharmaceuticals (ACXP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now

The board of Acurx Pharmaceuticals has approved the purchase of up to $1 million in bitcoin to hold as a treasury reserve asset.

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

STATEN ISLAND, N.Y. , Nov. 20, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin to hold as a treasury reserve asset.

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Acurx is proud to sponsor this inaugural Scientific Symposium of the Peggy Lillis Foundation (PLF) for C. Diff Education & Advocacy An update of ibezapolstat Ph2b clinical and microbiome results was presented Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C.

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Thomas Yip - H.C. Wainwright John Stinson - Private Investor Operator Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third Quarter 2024 Results and Business Update Conference Call.

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

STATEN ISLAND, N.Y. , Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024.

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 trials showed a 96% cure rate, positioning it as a potential game-changer with no preexisting resistance and minimal microbiome impact. The company's second asset showed activity against drug-resistant anthrax, making it a possible candidate for government funding.

Acurx Ready To Expand Pipeline With Anthrax Treatment

The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C.

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

STATEN ISLAND, N.Y.  , Oct. 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will participate in the Spartan Capital inaugural investor conference on November 4, 2024 at the Pierre Hotel in New York, New York.

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

STATEN ISLAND, N.Y. , Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024 at 8:00 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign. NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The Street, one of the leading U.S. business television platforms, is pleased to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company.

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Zapp Electric Vehicles Group Ltd

Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week NEW YORK, NY / ACCESSWIRE / October 11, 2024 / New to The Street, the leading platform for showcasing innovative companies, is proud to announce its upcoming sponsored programming on Bloomberg TV airing Saturday, October 11, at 6:30 PM EST. The lineup includes ZAPP, NUBURU, and ACURX Pharmaceuticals, each bringing cutting-edge advancements in electric vehicles, blue laser technology, and antibiotic innovation to the forefront.

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

New analyses extend data on beneficial effects of ibezapolstat on the gut microbiome Confirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic concentrations Selected ACX-375 analogues demonstrated in vitro activity against Anthrax (B. anthracis), a Bioterrorism Category A pathogen, including activity against ciprofloxacin resistant Anthrax.

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target Mechanistic findings explain ibezapolstat's properties of lacking cross resistance with other antibiotics and not fostering the emergence of Enterococcus, including vancomycin-resistant strains, a unique differentiation among anti-CDI antibiotics Molecular structure data will be used to guide rational design of new systemic therapeutic compounds with improved inhibitory activity and PK characteristics Planning continues to prepare to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI) Acurx is also preparing requests for regulatory guidance to initiate clinical trials in the European Union, the United Kingdom, Japan and Canada Ibezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA STATEN ISLAND, N.Y.

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

September 9-11, 2024 STATEN ISLAND, N.Y. , Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), today announced it will be featured as a presenting company at the H.C.

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2024 Earnings Conference Call August 9, 2024 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President & CEO Robert DeLuccia - Executive Chairman Conference Call Participants Jason McCarthy - Maxim Group Thomas Yip - H.C. Wainwright James Molloy - Alliance Global Partners Operator Greetings.

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

STATEN ISLAND, N.Y. , Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024.

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the United States Patent and Trademark Office (USPTO) on July 16, 2024.

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2024 financial results on Friday, August 9, 2024 at 8:00 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treated patients with C. difficile Infection (CDI) Results consistent with those shown in earlier human volunteer studies and Phase 2a studies Preservation and increased concentrations of beneficial Firmicute (Bacilotta) phylum known to be involved in bile acid homeostasis and short chain fatty acid metabolism was demonstrated Actinobacteria and Bacteroides preservation also confirmed using quantitative analysis STATEN ISLAND, N.Y.

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President and CEO Robert DeLuccia - Executive Chairman Conference Call Participants Ed Arce - H.C. Wainwright James Molloy - Alliance Global Partners Operator Hello, and welcome to the Acurx Pharmaceuticals First Quarter 2024 Financial Results Conference Call.

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial program Agreement also reached with FDA on complete non-clinical and clinical development plan for filing of a New Drug Application for marketing approval Planning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI) SME (Small and Medium-sized Enterprise) designation has been granted by the EMA (European Medicines Agency), which allows Acurx to benefit from fee incentives and other support from the EMA for EU Marketing Authorization Acurx is now preparing to submit requests for guidance to initiate clinical trials in the European Union, the United Kingdom, Japan and Canada Ibezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA STATEN ISLAND, N.Y.

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

STATEN ISLAND, N.Y. , May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2024.

News for Acurx Pharmaceuticals LLC Stock (ACXP)